Form 4: Oncology Institute's Chief Medical Officer Acquires Shares and Warrants in Private Placement

Yale Podnos, Chief Medical Officer of Oncology Institute, acquires shares and warrants through a private placement, increasing his holdings in the company.

Summary

• Yale Podnos, the Chief Medical Officer of Oncology Institute, acquired 9,056 shares of common stock and 4,528 common warrants on March 26, 2025.
• The acquisition was part of a private placement transaction directly from the company.
• Each private placement unit, consisting of two shares of common stock and one common warrant, was purchased for $2.2084.
• The cost per share of common stock was $1.0417, and the cost per common warrant was $0.1250.
• Following the transaction, Podnos directly owns 79,049 shares of common stock and 4,528 common warrants.
• The warrants are exercisable immediately and expire on March 26, 2030.
• Podnos is restricted from exercising the warrants if it would result in him owning more than 4.99% of the company's outstanding common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The Chief Medical Officer's participation in a private placement suggests confidence, but the dilution effect on existing shareholders is a potential concern.

Positives

• The Chief Medical Officer's investment in the company through a private placement could be seen as a positive signal.
• The private placement provides the company with additional capital.

Risks

• The warrant exercise limitation could restrict the potential upside for the reporting person.
• The private placement could dilute existing shareholders' ownership.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Management Comments

• The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the 'Exchange Act').

Industry Context

This type of transaction is common in the biotech and pharmaceutical industries, where companies often raise capital through private placements to fund research and development or operations.

Comparison to Industry Standards

• Private placements are a common method for companies, especially smaller ones in the biotech sector like Oncology Institute, to raise capital.
• Comparable companies might include other oncology-focused firms that have utilized private placements, such as Xometry Inc. or Adaptive Biotechnologies Corp., though the specifics of each placement (size, terms, participants) can vary widely.
• The pricing of the units and warrants would need to be compared to similar placements in the industry to assess whether the terms are favorable or unfavorable to the company and the investor.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares in the private placement.
• The company benefits from the additional capital raised through the private placement.

Key Dates

Keywords

private placement, common warrant, common stock, Oncology Institute, Podnos, acquisition, beneficial ownership